Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Molecular determinants of loperamide and N-desmethyl loperamide binding in the hERG cardiac K+ channel.

Vaz RJ, Kang J, Luo Y, Rampe D.

Bioorg Med Chem Lett. 2017 Dec 15. pii: S0960-894X(17)31181-2. doi: 10.1016/j.bmcl.2017.12.020. [Epub ahead of print]

PMID:
29274816
2.

Observations on conducting whole-cell patch clamping of the hERG cardiac K+ channel in pure human serum.

Kang J, Luo Y, Searles M, Rampe D.

J Appl Toxicol. 2017 Apr;37(4):445-453. doi: 10.1002/jat.3377. Epub 2016 Aug 24.

PMID:
27553911
3.

Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic.

Kang J, Compton DR, Vaz RJ, Rampe D.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Oct;389(10):1133-7. doi: 10.1007/s00210-016-1286-7. Epub 2016 Aug 16.

PMID:
27530870
4.

A Festschrift in honor of David J. Triggle.

Gopalakrishnan M, Rampe D, Triggle C.

Biochem Pharmacol. 2015 Nov 15;98(2):267-8. doi: 10.1016/j.bcp.2015.08.100. Epub 2015 Aug 22. No abstract available.

PMID:
26307541
5.

On Becoming a Pharmacologist: Channeling David Triggle.

Rampe D, Gopalakrishnan M.

Biochem Pharmacol. 2015 Nov 15;98(2):292-8. doi: 10.1016/j.bcp.2015.08.002. Epub 2015 Aug 5. Review.

PMID:
26254590
6.

A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.

Fermini B, Hancox JC, Abi-Gerges N, Bridgland-Taylor M, Chaudhary KW, Colatsky T, Correll K, Crumb W, Damiano B, Erdemli G, Gintant G, Imredy J, Koerner J, Kramer J, Levesque P, Li Z, Lindqvist A, Obejero-Paz CA, Rampe D, Sawada K, Strauss DG, Vandenberg JI.

J Biomol Screen. 2016 Jan;21(1):1-11. doi: 10.1177/1087057115594589. Epub 2015 Jul 13. Review.

PMID:
26170255
7.
8.

A history of the role of the hERG channel in cardiac risk assessment.

Rampe D, Brown AM.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):13-22. doi: 10.1016/j.vascn.2013.03.005. Epub 2013 Mar 26.

PMID:
23538024
9.

Ca²⁺ channel activators reveal differential L-type Ca²⁺ channel pharmacology between native and stem cell-derived cardiomyocytes.

Kang J, Chen XL, Ji J, Lei Q, Rampe D.

J Pharmacol Exp Ther. 2012 May;341(2):510-7. doi: 10.1124/jpet.112.192609. Epub 2012 Feb 21.

10.

Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat.

Meng H, Cao J, Kang J, Ying X, Ji J, Reynolds W, Rampe D.

Toxicol Lett. 2012 Jan 5;208(1):62-8. doi: 10.1016/j.toxlet.2011.10.010. Epub 2011 Oct 18.

PMID:
22037396
11.

Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.

Corbier A, Le Berre N, Rampe D, Meng H, Lorenz M, Vicat P, Potdevin S, Doubovetzky M.

Toxicol Sci. 2011 Jun;121(2):417-27. doi: 10.1093/toxsci/kfr072. Epub 2011 Mar 24.

PMID:
21436127
12.

Manual whole-cell patch-clamping of the HERG cardiac K+ channel.

Chen XL, Kang J, Rampe D.

Methods Mol Biol. 2011;691:151-63. doi: 10.1007/978-1-60761-849-2_9.

PMID:
20972752
13.

In vitro electrocardiographic and cardiac ion channel effects of (-)-epigallocatechin-3-gallate, the main catechin of green tea.

Kang J, Cheng H, Ji J, Incardona J, Rampe D.

J Pharmacol Exp Ther. 2010 Aug;334(2):619-26. doi: 10.1124/jpet.110.169391. Epub 2010 May 18.

14.

In Vitro electrophysiological activity of nerispirdine, a novel 4-aminopyridine derivative.

Smith C, Kongsamut S, Wang H, Ji J, Kang J, Rampe D.

Clin Exp Pharmacol Physiol. 2009 Nov;36(11):1104-9. doi: 10.1111/j.1440-1681.2009.05200.x. Epub 2009 Apr 27.

PMID:
19413590
15.

Functional interaction between DPI 201-106, a drug that mimics congenital long QT syndrome, and sevoflurane on the guinea-pig cardiac action potential.

Kang J, Chen XL, Reynolds WP, Rampe D.

Clin Exp Pharmacol Physiol. 2007 Dec;34(12):1313-6. Epub 2007 Sep 24.

PMID:
17892500
16.

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K.

J Pharmacol Toxicol Methods. 2006 Sep-Oct;54(2):116-29. Epub 2006 May 9.

PMID:
16843688
17.

Mechanisms underlying the QT interval-prolonging effects of sevoflurane and its interactions with other QT-prolonging drugs.

Kang J, Reynolds WP, Chen XL, Ji J, Wang H, Rampe DE.

Anesthesiology. 2006 May;104(5):1015-22.

PMID:
16645454
18.

Predictive models for hERG potassium channel blockers.

Cianchetta G, Li Y, Kang J, Rampe D, Fravolini A, Cruciani G, Vaz RJ.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3637-42.

PMID:
15978804
19.

Human ether-a-go-go related gene (HERG): a chemist's perspective.

Vaz RJ, Li Y, Rampe D.

Prog Med Chem. 2005;43:1-18. Review. No abstract available.

PMID:
15850821
20.

Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists.

Merriman GH, Ma L, Shum P, McGarry D, Volz F, Sabol JS, Gross A, Zhao Z, Rampe D, Wang L, Wirtz-Brugger F, Harris BA, Macdonald D.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):435-8.

PMID:
15603968
21.

Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.

Kang J, Chen XL, Wang H, Ji J, Cheng H, Incardona J, Reynolds W, Viviani F, Tabart M, Rampe D.

Mol Pharmacol. 2005 Mar;67(3):827-36. Epub 2004 Nov 17.

22.

Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.

Gögelein H, Brendel J, Steinmeyer K, Strübing C, Picard N, Rampe D, Kopp K, Busch AE, Bleich M.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Sep;370(3):183-92. Epub 2004 Aug 31.

PMID:
15340774
23.

Pentamidine-induced long QT syndrome and block of hERG trafficking.

Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W, Rampe D.

J Pharmacol Exp Ther. 2005 Jan;312(1):316-23. Epub 2004 Aug 31.

24.
25.

Cardiac ion channel effects of tolterodine.

Kang J, Chen XL, Wang H, Ji J, Reynolds W, Lim S, Hendrix J, Rampe D.

J Pharmacol Exp Ther. 2004 Mar;308(3):935-40. Epub 2004 Jan 7.

26.

Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.

Pearlstein R, Vaz R, Rampe D.

J Med Chem. 2003 May 22;46(11):2017-22. Review. No abstract available.

PMID:
12747773
27.

Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.

Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D.

Bioorg Med Chem Lett. 2003 May 19;13(10):1829-35.

PMID:
12729675
28.

Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K+ channels.

Kang J, Chen XL, Wang H, Rampe D.

Eur J Pharmacol. 2003 Jan 1;458(1-2):25-9.

PMID:
12498903
29.

A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.

Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D.

Eur J Pharmacol. 2002 Aug 16;450(1):37-41.

PMID:
12176106
30.

Development and evaluation of high throughput functional assay methods for HERG potassium channel.

Tang W, Kang J, Wu X, Rampe D, Wang L, Shen H, Li Z, Dunnington D, Garyantes T.

J Biomol Screen. 2001 Oct;6(5):325-31.

PMID:
11689132
31.
32.

The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel.

Kang J, Chen XL, Rampe D.

Biochem Biophys Res Commun. 2001 Aug 24;286(3):499-504.

PMID:
11511086
33.
34.

Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

Kang J, Wang L, Chen XL, Triggle DJ, Rampe D.

Mol Pharmacol. 2001 Jan;59(1):122-6.

35.

Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.

Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D.

J Pharmacol Exp Ther. 2000 Nov;295(2):614-20.

36.

High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide.

Kang J, Wang L, Cai F, Rampe D.

Eur J Pharmacol. 2000 Mar 31;392(3):137-40.

PMID:
10762666
37.

Cardiovascular safety of fexofenadine HCl.

Pratt C, Brown AM, Rampe D, Mason J, Russell T, Reynolds R, Ahlbrandt R.

Clin Exp Allergy. 1999 Jul;29 Suppl 3:212-6.

PMID:
10444240
38.

The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.

Rampe D, Murawsky MK, Grau J, Lewis EW.

J Pharmacol Exp Ther. 1998 Aug;286(2):788-93.

40.

Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart.

Lacerda AE, Roy ML, Lewis EW, Rampe D.

Mol Pharmacol. 1997 Aug;52(2):314-22. Erratum in: Mol Pharmacol 1997 Oct;52(4):754.

41.

Stable expression and characterization of the human brain potassium channel Kv2.1: blockade by antipsychotic agents.

Wible B, Murawsky MK, Crumb WJ Jr, Rampe D.

Brain Res. 1997 Jun 27;761(1):42-50.

PMID:
9247064
42.

Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin.

Rampe D, Murawsky MK.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):743-50.

PMID:
9205959
43.

Voltage- and time-dependent block by perhexiline of K+ currents in human atrium and in cells expressing a Kv1.5-type cloned channel.

Rampe D, Wang Z, Fermini B, Wible B, Dage RC, Nattel S.

J Pharmacol Exp Ther. 1995 Jul;274(1):444-9.

PMID:
7616429
44.

Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart.

Rampe D, Wible B, Brown AM, Dage RC.

Mol Pharmacol. 1993 Dec;44(6):1240-5.

PMID:
8264561
45.

Verapamil blocks a rapidly activating delayed rectifier K+ channel cloned from human heart.

Rampe D, Wible B, Fedida D, Dage RC, Brown AM.

Mol Pharmacol. 1993 Sep;44(3):642-8.

PMID:
8371716
46.

Comparison of the in vitro and in vivo cardiovascular effects of two structurally distinct Ca++ channel activators, BAY K 8644 and FPL 64176.

Rampe D, Anderson B, Rapien-Pryor V, Li T, Dage RC.

J Pharmacol Exp Ther. 1993 Jun;265(3):1125-30.

PMID:
7685384
47.

New synthetic ligands for L-type voltage-gated calcium channels.

Rampe D, Triggle DJ.

Prog Drug Res. 1993;40:191-238. Review.

PMID:
8395066
48.

[3H]PN200-110 and [3H]glibenclamide binding in normal and cardiomyopathic hamsters.

Miller JA, Chmielewski PA, Rampe D.

Gen Pharmacol. 1992 Nov;23(6):1153-7.

PMID:
1336750
49.

Characterization of the effects of a new Ca2+ channel activator, FPL 64176, in GH3 cells.

Kunze DL, Rampe D.

Mol Pharmacol. 1992 Oct;42(4):666-70.

PMID:
1279375
50.

Supplemental Content

Support Center